Literature DB >> 4071371

Efficacy of elective lymph node dissection in 2,347 patients with clinical stage I malignant melanoma.

W H McCarthy, H M Shaw, G W Milton.   

Abstract

The results of a largely prospective but non-randomized study of 2,347 patients with clinical Stage I malignant melanoma have demonstrated that there are certain subgroups of patients who benefit substantially from ELND. Men with lesions of intermediate thickness (1.6 to 3.0 millimeters) benefited most from ELND, both in terms of disease-free and total survival rates. Ten year survival rates in patients who underwent ELND were more than 40 per cent higher than the rates in patients who underwent WE. Although total survival rates were not improved in patients with the thickest lesions (those in excess of 3.0 millimeters) disease-free rates in these patients were considerably higher after ELND. Women with lesions of the extremities thicker than 1.5 millimeters had significantly improved disease-free and total survival rates after ELND (ten year survival rates of up to 37 per cent higher after ELND). No women with lesions of the trunk appeared to benefit from this surgical procedure.

Entities:  

Mesh:

Year:  1985        PMID: 4071371

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  8 in total

Review 1.  Elective lymph node dissection for melanoma: two perspectives.

Authors:  W H McCarthy; H M Shaw; N Cascinelli; M Santinami; F Belli
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

2.  Skin malignancy and the reconstructive plastic surgeon.

Authors:  R W Griffiths
Journal:  Ann R Coll Surg Engl       Date:  1989-05       Impact factor: 1.891

3.  Should elective lymph node dissection be used for treatment of primary melanoma?

Authors:  B Biess; E B Bröcker; H Drepper; M Klein; A Lippold; A Peters
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence.

Authors:  B M Clary; M S Brady; J J Lewis; D G Coit
Journal:  Ann Surg       Date:  2001-02       Impact factor: 12.969

Review 5.  Cure and cosmesis in the management of primary malignant melanoma.

Authors:  G T Neades; L E Hughes
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

Review 6.  Sentinel lymph node biopsy progress in surgical treatment of cancer.

Authors:  T Schulze; A Bembenek; P M Schlag
Journal:  Langenbecks Arch Surg       Date:  2004-06-09       Impact factor: 3.445

7.  Desmoplastic melanoma: patterns of recurrence.

Authors:  B M Smithers; G R McLeod; J H Little
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

8.  Monoclonal antibody imaging of human melanoma. Radioimmunodetection by subcutaneous or systemic injection.

Authors:  M T Lotze; J A Carrasquillo; J N Weinstein; G J Bryant; P Perentesis; J C Reynolds; L A Matis; R R Eger; A M Keenan; I Hellström
Journal:  Ann Surg       Date:  1986-09       Impact factor: 12.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.